{"product_id":"mygn-ansoff-analysis","title":"(MYGN) Myriad Genetics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Myriad Genetics, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help with strategy, investing, or planning; this page includes a real preview of the analysis so you can judge style and substance. Purchase the full version to get the complete, ready-to-use company-specific Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyRisk U.S. adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyRisk Hereditary Cancer Test is already in the U.S. oncology and genetics referral flow, so the penetration play is to win more orders from the same channel, not change the product mix. That means higher test volume, better fixed-cost absorption, and more share in an existing inherited-cancer market. In Myriad Genetics, Inc.'s 2025 reporting, this matters because U.S. adoption is the fastest path to grow revenue without adding launch risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneSight prescriber growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneSight Psychotropic targets depression, anxiety, and ADHD medication selection, so prescriber growth is the core market-penetration lever in behavioral health and primary care. Deeper clinician adoption and more repeat testing can lift test volume without changing the product mix.\u003c\/p\u003e\n\u003cp\u003eMyriad Genetics said GeneSight reached over 1 million patient tests cumulatively, which shows real clinician traction. More repeat use should improve revenue per prescriber and strengthen share in the same prescribing base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen's health screening share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrequel Prenatal Screen and Foresight Carrier Screen already fit the U.S. women’s health market, which is tied to roughly 3.6 million annual births. Penetration comes from more orders in OB-GYN and maternal-fetal medicine clinics, not from a new market. Even a small share gain in these high-volume settings can lift test volume fast. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology prognostic test uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProlaris in prostate cancer and EndoPredict in breast cancer sit in existing urology and breast oncology pathways, so Myriad Genetics, Inc. is pushing deeper clinician ordering, not new disease areas. In 2025, the American Cancer Society estimated 313,780 new prostate cases and 316,950 invasive breast cancers in the U.S., giving the company large, recurring test pools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrow orders inside current care pathways\u003c\/li\u003e\n\u003cli\u003eTarget urologists and breast oncologists\u003c\/li\u003e\n\u003cli\u003eUse existing evidence to raise repeat use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompanion diagnostic utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBRACAnalysis CDx and MyChoice CDx already sit in oncology workflows for metastatic breast, ovarian, pancreatic, and prostate cancer, plus ovarian HRD testing. Myriad Genetics can grow market penetration by increasing test use at diagnosis and at treatment change points, where companion diagnostics guide therapy choice.\u003c\/p\u003e\n\u003cp\u003eThis is a workflow win, not a new market. As more oncologists use biomarker-led care, Myriad Genetics can lift share in an installed base that is already familiar with the tests and their clinical value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports treatment selection in oncology\u003c\/li\u003e\n\u003cli\u003eTargets metastatic and HRD-linked cancers\u003c\/li\u003e\n\u003cli\u003eExpands share through routine use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad’s Growth: More Tests Through Existing U.S. Care Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Myriad Genetics, Inc. means pushing more tests through the same U.S. care pathways, especially MyRisk, GeneSight, and women’s health screens. In 2025, the U.S. still offered large pools: 3.6 million annual births and 313,780 new prostate cancer cases. More repeat use and clinician adoption can lift volume without new launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTest\u003c\/th\u003e\n\u003cth\u003e2025 U.S. pull\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight\u003c\/td\u003e\n\u003ctd\u003e1M+ cumulative tests\u003c\/td\u003e\n\u003ctd\u003eMore prescribers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyRisk\u003c\/td\u003e\n\u003ctd\u003eLarge oncology referral base\u003c\/td\u003e\n\u003ctd\u003eMore orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Myriad Genetics, Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Ansoff Matrix view for Myriad Genetics, Inc. to simplify growth strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates reputable Myriad Genetics sources to verify Ansoff Matrix growth paths quickly and make strategy assumptions traceable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational test menu expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics can push its existing test menu into more countries without changing the core assays, which fits market development. The company already sells across the U.S. and international markets, so the upside is wider reach, not new product risk.\u003c\/p\u003e\n\u003cp\u003eThat matters because Myriad’s 2025 revenue base was still built on the same branded tests, so each new geography can add volume with limited R\u0026amp;D spend. One clean example: the same hereditary cancer and prenatal tests can be sold through local labs, payers, and physician networks in Europe and Asia.\u003c\/p\u003e\n\u003cp\u003eFor Myriad Genetics, this is a low-change, high-reach move: expand distribution, clear local reimbursement, and keep the menu intact. If international penetration rises even a few points, test volumes can grow faster than fixed costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIllumina channel expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc.'s alliance with Illumina, Inc. supports market development by widening germline and tumor testing access beyond Myriad Genetics' direct sales channels. It can use Illumina's installed sequencing base and partner network, which lowers market entry friction and speeds reach into labs that already run next-gen sequencing workflows. That matters because platform access is often the fastest path to new geographies and accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntermountain network expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. uses its Intermountain Precision Genomics tie-up to push into new health-system and regional referral channels, expanding access to germline and somatic tumor testing. Intermountain Health operates 33 hospitals, giving Myriad a wider clinical funnel and a stronger route into large, integrated care networks. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew specialty accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMarket development for Myriad Genetics means selling its existing oncology, women’s health, and mental health tests into new physician groups and health systems. New specialty account wins expand reach without new-product spend, so they can lift revenue faster than R\u0026amp;D. In FY2025, this model matters because the same test menu can be monetized across more sites of care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 core test areas\u003c\/li\u003e\n\u003cli\u003eMore accounts, same menu\u003c\/li\u003e\n\u003cli\u003eLower launch cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational clinical adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. can push MyRisk, GeneSight, and Prequel into non-U.S. clinics as the same assays in a new market. This fits precision medicine demand, which keeps rising as countries expand carrier screening, oncology risk testing, and pharmacogenomics adoption.\u003c\/p\u003e\n\u003cp\u003eInternational uptake is a scale play, not a product redesign. In FY2025, the key signal is that the addressable pool is far larger than Myriad Genetics, Inc.'s U.S.-only base, so even modest penetration can lift test volume and recurring assay revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame tests, new geography\u003c\/li\u003e\n\u003cli\u003eTargets growing precision medicine demand\u003c\/li\u003e\n\u003cli\u003eUses existing clinical evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad’s Growth Play: Same Tests, Wider Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics’ market development is about taking the same FY2025 test menu into new geographies and care networks, so growth comes from reach, not new assay risk. The Illumina link and Intermountain’s 33 hospitals widen access to oncology, women’s health, and mental health tests with limited launch cost.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLever\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntermountain Health\u003c\/td\u003e\n\u003ctd\u003e33 hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct set\u003c\/td\u003e\n\u003ctd\u003eSame FY2025 test menu\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth path\u003c\/td\u003e\n\u003ctd\u003eMore sites, same assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMyriad Genetics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology assay breadth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics already sells at least 6 oncology assays, including MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, and Precise Tumor, so product development here means widening the menu for the same customers. In FY2025, that matters because the company can lift test mix and repeat use without changing its core oncology buyer base. The play is to add new assays or larger panels, not chase a new market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRCA and HRD extension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. can extend its BRCA and HRD testing deeper into oncology by adding more tumor types and therapy-linked use cases. That fits product development because it builds on existing cancer diagnostics rather than entering new markets. In a 2025 oncology base where BRCA and HRD already guide PARP inhibitor use, broader test panels can raise clinical reach without changing the core customer set.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNA-based prognostic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProlaris uses a 46-gene cell-cycle score and EndoPredict uses a 12-gene panel, so Myriad Genetics, Inc. can extend RNA-based prognostics without rebuilding the lab workflow. Adding new prostate and breast cancer risk tools would deepen decision support for the same urologists and oncologists already using these tests. That can raise test breadth per clinician and improve uptake across a shared installed base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrenatal panel enhancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrenatal panel enhancement is a product-depth play: Prequel and Foresight already cover prenatal and carrier screening, so Myriad Genetics, Inc. can add more conditions, broader panel content, and sharper reports for women’s health providers and expectant parents. With about 3.6 million U.S. births a year, the demand base stays large.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand condition coverage\u003c\/li\u003e\n\u003cli\u003eRefine report clarity\u003c\/li\u003e\n\u003cli\u003eSell to current provider channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneSight content expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneSight content expansion fits product development: the test already uses DNA genotyping to guide psychotropic drug choice, and adding more pharmacogenomic markers or stronger clinical decision support can raise its utility without changing the core behavioral health buyer. In the U.S., more than 50% of patients with major depression do not respond to the first antidepressant, so better prescribing support has clear value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing behavioral health base\u003c\/li\u003e\n\u003cli\u003eAdds pharmacogenomic depth\u003c\/li\u003e\n\u003cli\u003eImproves prescribing decisions\u003c\/li\u003e\n\u003cli\u003eTargets high unmet need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad’s Installed Base Fuels Repeat-Test Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct development at Myriad Genetics, Inc. means adding new assays and stronger panels for the same oncology, prenatal, and behavioral health customers. In FY2025, this fits Myriad Genetics, Inc.’s installed base: MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Precise Tumor, Prequel, Foresight, and GeneSight already support repeat use. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e6+ assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrenatal\u003c\/td\u003e\n\u003ctd\u003e3.6M U.S. births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBehavioral health\u003c\/td\u003e\n\u003ctd\u003e50%+ first-try nonresponse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGermline and somatic integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. already serves two testing lines: germline and somatic tumor testing. Folding both into one precision medicine offer lets Myriad Genetics, Inc. sell more combined test panels and move into new diagnostic service mixes. That matters in a market where one cancer case can need both inherited-risk and tumor-profiling data for treatment choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-enabled diagnostic services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. can diversify by co-delivering diagnostic services with Illumina and Intermountain Precision Genomics, not just by selling stand-alone tests. That model opens access to hospitals and labs through partner channels and fits a service-led Ansoff diversification move. One offer can reach two care networks at once, widening adoption without building every route alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision medicine workflow offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. can use diversification to turn its oncology, women’s health, and mental health tests into one precision medicine workflow suite, shifting from stand-alone assays to integrated care support. That model can raise clinician stickiness and widen revenue per patient by embedding results, risk insights, and follow-up guidance into daily care paths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSomatic tumor service expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecise Tumor and MyChoice CDx show Myriad Genetics, Inc. can already support tumor testing, so diversification can widen that base into molecular pathology service lines. The move targets broader tumor decision support, not a single assay, and it can lift test utility across more oncology workflows.\u003c\/p\u003e\n\u003cp\u003eThis is an adjacent diversification play in the Ansoff Matrix: same cancer focus, wider service scope. It can deepen share in a larger lab market if Myriad Genetics, Inc. pairs assay data with interpretation, reporting, and clinician support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuild beyond one assay\u003c\/li\u003e\n\u003cli\u003eExpand into pathology services\u003c\/li\u003e\n\u003cli\u003eSell broader decision support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-indication genomics platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. already spans oncology, reproductive health, and mental health, so a multi-indication genomics platform is a true diversification play. By linking test menus, data, and clinician workflow across these three care areas, Company Name can widen adjacent-market reach and raise the lifetime value of each customer.\u003c\/p\u003e\n\u003cp\u003eThis matters because Myriad Genetics, Inc. has built clinical franchises in cancer risk, prenatal screening, and pharmacogenomics, giving it a broader base than a single-indication peer. The upside is cross-selling, shared lab infrastructure, and more usable genetic data across more than one disease area.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThree care areas already in place\u003c\/li\u003e\n\u003cli\u003eCross-sell across oncology, reproductive, psychiatry\u003c\/li\u003e\n\u003cli\u003eBroader base lowers single-market risk\u003c\/li\u003e\n\u003cli\u003eShared data can lift platform value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad Genetics Expands Into a Broader Precision-Medicine Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. can use diversification to move from separate tests into a broader precision-medicine platform across oncology, women’s health, and mental health. That widens revenue per patient, lifts cross-sell, and reduces reliance on any one assay line.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eTumor profiling and decision support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen’s health\u003c\/td\u003e\n\u003ctd\u003eRisk screening and follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMental health\u003c\/td\u003e\n\u003ctd\u003ePharmacogenomic guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234716098825,"sku":"mygn-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mygn-ansoff-matrix.webp?v=1785725810","url":"https:\/\/dcfanalyst.com\/products\/mygn-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}